Patents by Inventor Alison Tisdale

Alison Tisdale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11459386
    Abstract: Interleukin-6 (IL-6) antagonists are provided that are specific for binding to site II of IL-6. Methods of using such inhibitors to treat IL-6 related diseases, e.g., disease of the eye such as diabetic macular edema are disclosed.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: October 4, 2022
    Assignee: Sesen Bio, Inc.
    Inventors: Michael March Schmidt, Thomas M. Barnes, David V. Erbe, Eric Steven Furfine, Alison Tisdale
  • Publication number: 20220169719
    Abstract: Improved IL-6 antibodies are provided. Uses of the antibodies in the treatment of IL-6 related diseases, e.g., ocular diseases such as diabetic macular edema, are disclosed.
    Type: Application
    Filed: September 13, 2021
    Publication date: June 2, 2022
    Inventors: Michael March Schmidt, Alison Tisdale, Eric Steven Furfine, Grigorios Zarbis-Papastoitsis
  • Patent number: 11142571
    Abstract: Improved IL-6 antibodies are provided. Uses of the antibodies in the treatment of IL-6-related diseases, e.g., ocular diseases such as diabetic macular edema, are disclosed.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: October 12, 2021
    Assignee: SESEN BIO, INC.
    Inventors: Michael March Schmidt, Alison Tisdale, Eric Steven Furfine, Grigorios Zarbis-Papastoitsis
  • Patent number: 10947309
    Abstract: Improved IL-6 antibodies are provided. Uses of the antibodies in the treatment of IL-6-related diseases, e.g., ocular diseases such as diabetic macular edema, are disclosed.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: March 16, 2021
    Assignee: SESEN BIO, INC.
    Inventors: Michael March Schmidt, Alison Tisdale, Eric Steven Furfine, Grigorios Zarbis-Papastoitsis
  • Publication number: 20190194312
    Abstract: Improved IL-6 antibodies are provided. Uses of the antibodies in the treatment of IL-6 related diseases, e.g., ocular diseases such as diabetic macular edema, are disclosed.
    Type: Application
    Filed: November 6, 2015
    Publication date: June 27, 2019
    Inventors: Michael March Schmidt, Alison Tisdale, Eric Steven Furfine, Grigorios Zarbis-Papastoitsis
  • Publication number: 20180222975
    Abstract: IL-6 antagonists are provided that are specific for binding to site II of IL-6. Methods of using such inhibitors to treat IL-6 related diseases, e.g., disease of the eye such as diabetic macular edema are disclosed.
    Type: Application
    Filed: January 26, 2018
    Publication date: August 9, 2018
    Inventors: Michael March Schmidt, Thomas M. Barnes, David V. Erbe, Eric Steven Furfine, Alison Tisdale
  • Patent number: 9951130
    Abstract: Interleukin 6 (IL-6) antagonists are provided that are specific for binding to site II of IL-6. Methods of using such inhibitors to treat IL-6 related diseases, e.g., disease of the eye such as diabetic macular edema are disclosed.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: April 24, 2018
    Assignee: ELEVEN BIOTHERAPEUTICS, INC.
    Inventors: Michael March Schmidt, Thomas M. Barnes, David V. Erbe, Eric Steven Furfine, Alison Tisdale
  • Publication number: 20150125468
    Abstract: IL-6 antagonists are provided that are specific for binding to site II of IL-6. Methods of using such inhibitors to treat IL-6 related diseases, e.g., disease of the eye such as diabetic macular edema are disclosed.
    Type: Application
    Filed: October 7, 2014
    Publication date: May 7, 2015
    Applicant: ELEVEN BIOTHERAPEUTICS, INC.
    Inventors: Michael March Schmidt, Thomas M. Barnes, David V. Erbe, Eric Steven Furfine, Alison Tisdale